Shanghai Junshi Biosciences (HKG:1877, SHA:688180) received approval from China's National Medical Products Administration to market toripalimab injection, according to a Hong Kong Stock Exchange filing on May 21.
The drug, trading under the name Tuoyi, is used in combination with bevacizumab for the treatment of unresectable or metastatic hepatocellular carcinoma, the pharmaceutical company said.
Both of the company's Hong Kong and Shanghai shares slipped 1% in recent trade.
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。